Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02916056 · ClinicalTrials.gov registry record · Phase 3
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
A Phase 3 study, sponsored by vTv Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 297
- Enrollment target
NCT02916056: Clinical Trial Phase 3 study, sponsored by vTv Therapeutics.
NCT02916056 is a Phase 3 study that was terminated before completion, run by vTv Therapeutics. The registered enrollment target is 297 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02916056, a Phase 3 study, was terminated before completion, sponsored by vTv Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 297 participants
- Enrollment target
Study Summary
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
Interventions
- DRUG Azeliragon 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 3 |
Why NCT02916056 stopped before completion
NCT02916056 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Azeliragon 5mg is the first listed.
NCT02916056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02916056 about?
NCT02916056 is a clinical study titled "2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)". This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
What is the current status of trial NCT02916056?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 297 participants. The study started on 2016-12. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02916056?
The interventions under investigation include: Azeliragon 5mg (DRUG).
Who is sponsoring clinical trial NCT02916056?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02916056's enrollment target sits among peer trials
297 1163rd of 2000 higher than 837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia